Skip to content
Rossari Biotech logo

Rossari Biotech

ROSSARI NSE
₹420.40 +13.05 (+3.20%)
P/E
15.24
View as Markdown
MCP
Close 4 Nov 2026 ₹420.40 −219.55 −34.3% 1Y
Start ₹639.95

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
13.30%
Debt to Equity
0.28
EPS (TTM)
₹27.58
Book Value
₹254.11
Market Cap
—
P/E (TTM)
15.24
P/B
1.65
ROE
10.80%
Dividend Yield
0.12%
EBITDA
₹308 Cr
52W High
₹653.50
52W Low
₹375.00
Day Range
₹405.40 – ₹425.00
Volume
44,135

Peer Comparison

Commodities › Chemicals › Specialty Chemicals

Rossari Biotech peer comparison
Pidilite Industries
₹1,510.2058.04₹1,54,107 Cr13.721.42%23.90%31.00%₹15,399 Cr₹2,677 Cr
Gujarat Fluorochemicals
₹4,613.3083.76₹49,073 Cr6.040.07%7.82%9.64%₹5,303 Cr₹600 Cr
Navin Fluorine International
₹8,785.0057.03₹44,060 Cr10.100.09%19.60%21.00%₹3,634 Cr₹789 Cr
Deepak Nitrite
₹1,578.4027.48₹20,919 Cr3.320.49%9.82%11.40%₹8,575 Cr₹784 Cr
Aether Industries
₹1,540.7086.90₹20,030 Cr7.880.00%9.66%11.90%₹1,231 Cr₹235 Cr
Aarti Industries
₹447.5530.57₹15,838 Cr2.590.23%7.13%6.86%₹9,010 Cr₹531 Cr
Atul
₹5,156.5019.67₹14,827 Cr2.310.59%11.50%14.90%₹6,969 Cr₹788 Cr
Rossari Biotech (this company)
₹420.4015.24₹2,269 Cr1.650.12%10.80%13.30%₹2,661 Cr₹153 Cr
Median 8 companies₹1,559.5543.80₹20,474 Cr4.680.18%10.31%12.60%₹6,136 Cr₹692 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

Category scores

Quality
46
Average
Returns, margins, earnings quality 22% weight
Valuation
46
Average
Cheap vs sector & own history 24% weight
Growth
73
Strong
Sales & profit trajectory 9% weight
Financial Health
43
Weak
Solvency, leverage, coverage 9% weight
Momentum
18
Poor
Trend strength, vol-adjusted 12% weight
Ownership
21
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 62.4 days to 48.6 days

Weaknesses

2
  • Company has a low return on equity of 12.0% over last 3 years.
  • Dividend payout has been low at 2.00% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish775
OscillatorsNeutral171
Moving AveragesStrong Bearish604

Key readings

RSI (14)
48.13
Neutral
MACD (12,26,9)
−9.22
Bullish
SMA (50)
440.94
Bearish
SMA (200)
487.34
Bearish

As of

Analyst Rating

Based on 4 analysts
BUY75%

3 of 4 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
3
75%
HOLD
1
25%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
5Y+27.58%
3Y+13.10%
1Y+15.19%
TTM+19.75%

Net profit

Net profit growth by window
5Y+13.25%
3Y+11.67%
1Y+9.56%
TTM+11.68%

Operating cash flow

Operating cash flow growth by window
5Y+6.25%
3Y−24.66%
1Y−52.55%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−5.55 pp
3Y−1.53 pp
1Y−0.80 pp
TTM−0.53 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹516 Cr
Mar 2020₹600 Cr
Mar 2021₹709 Cr
Mar 2022₹1,483 Cr
Mar 2023₹1,656 Cr
Mar 2024₹1,831 Cr
Mar 2025₹2,080 Cr
Mar 2026₹2,396 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹46.00 Cr
Mar 2020₹65.00 Cr
Mar 2021₹80.00 Cr
Mar 2022₹98.00 Cr
Mar 2023₹107 Cr
Mar 2024₹131 Cr
Mar 2025₹136 Cr
Mar 2026₹149 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹335 Cr +8.5% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Rossari Biotech trades at a market cap of ₹2,970 Cr with a PE of 19.4x and has delivered 5-year sales CAGR of 28%, though profitability growth has lagged at 11% CAGR over the same period. The stock has underperformed significantly with a 1-year return of -24% and 3-year CAGR of -16%, while ROE remains modest at 11-12%.

Bull Case 7
  • Strong 5-year compounded sales growth of 28% indicates robust top-line expansion and market share gains in specialty chemicals
  • TTM revenue growth of 15% shows continued momentum in sales despite broader market headwinds
  • Working capital days improved significantly from 62.4 days to 48.6 days, freeing up cash and improving capital efficiency
  • PE of 19.4x is reasonable for a specialty chemicals company with double-digit sales growth, suggesting valuation is not stretched
  • Price-to-book of 2.17x is modest relative to the 5-year compounded sales growth of 28%, indicating potential value if growth sustains
  • 5-year compounded profit growth of 11% demonstrates the company has been able to scale profitability alongside revenue growth over the medium term
  • Stock decline of -24% over 1 year and -16% CAGR over 3 years means the stock is trading well below its historical highs, compressing valuation multiples
Bear Case 8
  • Stock has delivered -24% return over 1 year and -16% CAGR over 3 years, reflecting sustained negative market sentiment
  • TTM profit growth is -1%, indicating margin compression and inability to convert revenue growth into bottom-line expansion
  • 3-year ROE of only 12% is low for a specialty chemicals company, suggesting suboptimal capital allocation
  • Wide gap between 5-year sales CAGR of 28% and profit CAGR of 11% signals deteriorating operating leverage or rising input costs eating into margins
  • Dividend payout of only 2% of profits over the last 3 years provides negligible shareholder returns, with dividend yield at just 0.1%
  • Last year ROE dropped to 11% from the 5-year average of 13%, showing a declining return trend on equity deployed
  • 5-year stock CAGR of -15% despite 28% sales CAGR suggests the market is pricing in structural concerns about profitability sustainability
  • 3-year profit CAGR of only 8% compared to 13% sales CAGR over the same period shows persistent margin headwinds

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Rossari Biotech is making progress on sustainability with a significant 37% cut in Scope 1 emissions and expanding its international footprint via a new Thailand blending facility. No material headwinds emerged in the recent news cycle. The trend appears constructive with geographic diversification into Southeast Asia and improving ESG metrics, though investors should watch for revenue growth and margin updates at upcoming meets.

Positives 2
  • Scope 1 emissions cut 37% Jun 29

    Rossari Biotech reduced Scope 1 emissions by 37.25% in FY26, driven by lower diesel consumption. Energy and water intensity also improved alongside increased waste recycling.

  • Thailand facility goes live Jun 26

    Subsidiary Unistar Thai established a blending facility in Thailand with 5000 MTPA capacity to serve the Southeast Asian market.

Neutral 2
  • Record date for dividend fixed Jun 18

    Record date set for July 10, 2026 for dividend payment. 17th AGM scheduled for July 20, 2026.

  • Investor meet scheduled Jun 8

    Virtual investor and analyst meet held on June 12, 2026 to discuss public financial information.

Quarterly Results

₹ Cr
ROSSARI quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
483
464
473
490
498
513
580
544
586
582
685
697
698
Expenses
420
400
409
425
432
448
510
476
514
513
608
617
611
Operating Profit
64
64
64
65
66
65
69
68
72
69
77
81
87
OPM %
13%
14%
13%
13%
13%
13%
12%
12%
12%
12%
11%
12%
12%
Other Income
1
4
0.39
1
1
1
2
1.2
2
1
20
3.19
1
Interest
5
4
3
4
4
5
6
6
6
8
9
11
9
Depreciation
15
15
16
15
15
18
18
18
18
20
24
26
30
PBT
45
48
45.39
47
48
42
48
46
49.2
43
64
47.22
49
Tax %
26%
28%
25%
26%
27%
25%
28%
27%
26%
23%
28%
26%
21%
Net Profit
33
34
34
35
35
32
34
34
37
33
46
35
39
EPS (₹)
5.97
6.23
6.18
6.32
6.39
5.73
6.22
6.07
6.66
5.92
8.3
6.34
7.02

Profit & Loss

₹ Cr
ROSSARI profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
516
600
709
1,483
1,656
1,831
2,080
2,396
2,661
Expenses
438
495
586
1,299
1,433
1,581
1,815
2,110
2,348
Operating Profit
78
105
124
184
223
250
265
286
314
OPM %
15%
17%
17%
12%
13%
14%
13%
12%
12%
Other Income
1
4
9
13
6
8
4.01
24
25
Interest
3
4
3
13
22
19
18
29
36
Depreciation
12
17
23
48
63
60
67
79
99
PBT
63
88
107
136
144
178
184
203
204
Tax %
28%
26%
25%
28%
26%
26%
26%
26%
—
Net Profit
46
65
80
98
107
131
136
149
153
EPS (₹)
9.44
12.86
15.45
17.74
19.45
23.66
24.63
26.94
27.58
Div. Payout %
0%
4%
3%
3%
3%
2%
2%
2%
—

Balance Sheet

₹ Cr
ROSSARI balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
4
10
10
11
11
11
11
11
11
Reserves
119
277
398
794
904
1,037
1,174
1,322
1,397
Borrowings
8
67
0
8
74
119
218
436
388
Other Liabilities
118
118
152
442
375
401
482
505
564
Total Liabilities
250
471
561
1,255
1,364
1,567
1,886
2,274
2,359
Fixed Assets
74
94
181
607
585
578
598
784
845
CWIP
3
22
0
1
16
47
140
173
156
Investments
0
18
0
36
51
63
84
62
30
Other Assets
173
338
379
611
712
880
1,063
1,254
1,328
Total Assets
250
471
561
1,255
1,364
1,567
1,886
2,274
2,359

Cash Flow

₹ Cr
ROSSARI cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
71
57
48
29
152
43
137
65
Investing
−37
−190
−37
−299
−181
−103
−183
−220
Financing
−29
157
−25
292
61
16
65
186
Net Cash Flow
5
23
−14
22
32
−44
19
31
Free Cash Flow
27
−19
−8
−7
120
−83
−21
−175
CFO/EBITDA
118
74
64
43
89
39
74
47

Ratios

ROSSARI financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
57
74
75
78
85
83
85
Inventory Days
59
57
75
63
59
80
90
88
Days Payable
114
95
104
61
56
62
73
71
Cash Conversion Cycle
6
19
46
76
80
103
101
103
Working Capital Days
23
22
60
62
49
70
69
49
ROCE %
—
38%
29%
24%
18%
18%
16%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Rossari Biotech insights

64 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 68.14%
  • DIIs 14.19%
  • Public 13.79%
  • Others 2.04%
  • FIIs 1.84%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Rossari Biotech

What does Rossari Biotech Ltd do?
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India.
Where is Rossari Biotech Ltd (ROSSARI) listed?
Rossari Biotech Ltd trades as ROSSARI on the NSE and under code 543213 on the BSE.
Which sector does Rossari Biotech Ltd belong to?
Rossari Biotech Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the PE ratio of Rossari Biotech Ltd?
Rossari Biotech Ltd trades at a PE ratio of 15.24 as of 4 Nov 2026, on earnings per share of ₹27.58, against a book value of ₹254.11 per share.
What is the 52-week high and low of Rossari Biotech Ltd?
Over the last 52 weeks Rossari Biotech Ltd has traded between ₹375 and ₹653.5 as of 4 Nov 2026.
Does Rossari Biotech Ltd pay dividends?
Rossari Biotech Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Rossari Biotech Ltd?
Rossari Biotech Ltd reported a return on equity of 10.80%. Its debt-to-equity ratio is 0.28.

Company Information

Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India.

Website rossari.com
Listed 23 Jul 2020
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ROSSARI.md for Rossari Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month